TrimRx's Blog

Mounjaro isn’t FDA-approved for ADHD. However, research shows GLP-1 agonists may influence dopamine regulation and impulse control in ADHD patients.

Mounjaro reduces systolic blood pressure by 4-7 mmHg independent of weight loss through improved insulin sensitivity and reduced inflammation.

Cycling off Mounjaro requires structured tapering over 4–8 weeks to minimize rebound weight gain and metabolic adaptation—here’s the medical protocol.

Mounjaro and statins can be taken together safely in most cases, but timing, monitoring, and muscle-related side effects require clinical oversight.

Mounjaro maintenance dose ranges from 5mg to 15mg weekly depending on tolerance and metabolic response — here’s how to find yours without plateauing.

Mounjaro (tirzepatide) isn’t a thyroid drug, but thyroid conditions affect GLP-1 safety. Here’s what endocrinologists check before prescribing.

Weight regain after Mounjaro occurs in 60–70% of patients who stop treatment. Learn the biological mechanisms behind rebound weight gain and

Switching from Mounjaro to semaglutide requires dose conversion, retitration, and side effect management. Here’s what your prescriber won’t always mention

Mounjaro delivers 15–22% weight loss over 72 weeks with weekly injections. Bariatric surgery achieves 25–35% reduction but requires permanent anatomical